Lisa H Cazares

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/361096/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Research, 2002, 62, 3609-14.	0.9	630
2	Boosted Decision Tree Analysis of Surface-enhanced Laser Desorption/Ionization Mass Spectral Serum Profiles Discriminates Prostate Cancer from Noncancer Patients. Clinical Chemistry, 2002, 48, 1835-1843.	3.2	414
3	Evaluation of Serum Protein Profiling by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for the Detection of Prostate Cancer: I. Assessment of Platform Reproducibility. Clinical Chemistry, 2005, 51, 102-112.	3.2	336
4	Tissue Imaging Using Nanospray Desorption Electrospray Ionization Mass Spectrometry. Analytical Chemistry, 2012, 84, 141-148.	6.5	278
5	Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer and Prostatic Diseases, 1999, 2, 264-276.	3.9	239
6	Imaging Mass Spectrometry of a Specific Fragment of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase 2 Discriminates Cancer from Uninvolved Prostate Tissue. Clinical Cancer Research, 2009, 15, 5541-5551.	7.0	178
7	SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology, 2005, 41, 634-642.	7.3	132
8	Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clinical Cancer Research, 2002, 8, 2541-52.	7.0	131
9	SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer. Clinical Chemistry, 2008, 54, 53-60.	3.2	128
10	Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample Bias. Clinical Chemistry, 2008, 54, 44-52.	3.2	126
11	A Multicomponent Animal Virus Isolated from Mosquitoes. Cell Host and Microbe, 2016, 20, 357-367.	11.0	123
12	Serum Protein Profiles to Identify Head and Neck Cancer. Clinical Cancer Research, 2004, 10, 1625-1632.	7.0	110
13	Identification of Patients With Head and Neck Cancer Using Serum Protein Profiles. JAMA Otolaryngology, 2004, 130, 98.	1.2	107
14	Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clinical Chemistry, 2002, 48, 1835-43.	3.2	103
15	Quantification of circulating <i>Mycobacterium tuberculosis</i> antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3969-3974.	7.1	93
16	Surfaced-Enhanced Laser Desorption/Ionization Time-of-Flight (SELDI-TOF) Differentiation of Serum Protein Profiles of BRCA-1 and Sporadic Breast Cancer. Annals of Surgical Oncology, 2004, 11, 907-914.	1.5	88
17	MALDI tissue imaging: from biomarker discovery to clinical applications. Analytical and Bioanalytical Chemistry, 2011, 401, 17-27.	3.7	87
18	Turnover of Extracellular DNA in Eutrophic and Oligotrophic Freshwater Environments of Southwest Florida. Applied and Environmental Microbiology, 1989, 55, 1823-1828.	3.1	87

#	Article	IF	CITATIONS
19	Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Antiviral Research, 2018, 151, 97-104.	4.1	76
20	SELDI-TOF Serum Profiling for Prognostic and Diagnostic Classification of Breast Cancers. Disease Markers, 2004, 19, 229-238.	1.3	75
21	High Infection Rates for Adult Macaques after Intravaginal or Intrarectal Inoculation with Zika Virus. Emerging Infectious Diseases, 2017, 23, 1274-1281.	4.3	74
22	Data Reduction Using a Discrete Wavelet Transform in Discriminant Analysis of Very High Dimensionality Data. Biometrics, 2003, 59, 143-151.	1.4	70
23	Differential Capture of Serum Proteins for Expression Profiling and Biomarker Discovery in Pre―and Posttreatment Head and Neck Cancer Samples. Laryngoscope, 2008, 118, 61-68.	2.0	70
24	MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma. Proteomics, 2014, 14, 924-935.	2.2	67
25	Chikungunya Arthritis Mechanisms in the Americas. Arthritis and Rheumatology, 2018, 70, 585-593.	5.6	63
26	Serum, salivary and tissue proteomics for discovery of biomarkers for head and neck cancers. Expert Review of Molecular Diagnostics, 2005, 5, 93-100.	3.1	54
27	Serum Proteomic Biomarker Discovery Reflective of Stage and Obesity in Breast Cancer Patients. Journal of the American College of Surgeons, 2009, 208, 970-978.	O.5	49
28	Development of a Parallel Reaction Monitoring Mass Spectrometry Assay for the Detection of SARS-CoV-2 Spike Glycoprotein and Nucleoprotein. Analytical Chemistry, 2020, 92, 13813-13821.	6.5	47
29	Sphingosine kinase 2 is a chikungunya virus host factor co-localized with the viral replication complex. Emerging Microbes and Infections, 2015, 4, 1-9.	6.5	44
30	Using boronolectin in MALDI-MS imaging for the histological analysis of cancer tissue expressing the sialyl Lewis X antigen. Chemical Communications, 2011, 47, 10338.	4.1	43
31	Serum Biomarkers to Differentiate Benign and Malignant Mammographic Lesions. Journal of the American College of Surgeons, 2007, 204, 1065-1071.	0.5	39
32	Characterization of a Staphylococcus aureus USA300 protein signature using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Journal of Medical Microbiology, 2012, 61, 640-644.	1.8	37
33	Discrete serum protein signatures discriminate between human retrovirus-associated hematologic and neurologic disease. Leukemia, 2005, 19, 1229-1238.	7.2	36
34	The search for biomarkers of human embryo developmental potential in IVF: a comprehensive proteomic approach. Molecular Human Reproduction, 2013, 19, 250-263.	2.8	34
35	CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis. BMC Cancer, 2017, 17, 834.	2.6	34
36	Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus. Antiviral Research, 2018, 151, 50-54.	4.1	31

#	Article	IF	CITATIONS
37	Precision enhancement of MALDIâ€TOF MS using high resolution peak detection and labelâ€free alignment. Proteomics, 2008, 8, 1530-1538.	2.2	27
38	Optimization of MALDI-TOF MS Detection for Enhanced Sensitivity of Affinity-Captured Proteins Spanning a 100 kDa Mass Range. Journal of Proteome Research, 2007, 6, 4517-4524.	3.7	26
39	Mining the low molecular weight proteome of blood. Proteomics - Clinical Applications, 2007, 1, 758-768.	1.6	26
40	Tight junctions and mucin mRNA in BEAS-2B cells. In Vitro Cellular and Developmental Biology - Animal, 1995, 31, 738-740.	1.5	25
41	Measurement Reproducibility in the Early Stages of Biomarker Development. Disease Markers, 2004, 20, 295-307.	1.3	25
42	A Bayesian network approach to feature selection in mass spectrometry data. BMC Bioinformatics, 2010, 11, 177.	2.6	21
43	Challenges to Developing Proteomic-Based Breast Cancer Diagnostics. OMICS A Journal of Integrative Biology, 2011, 15, 251-259.	2.0	21
44	Thermal inactivation of enzymes and pathogens in biosamples for MS analysis. Bioanalysis, 2015, 7, 1885-1899.	1.5	20
45	MALDI/SELDI Protein Profiling of Serum for the Identification of Cancer Biomarkers. Methods in Molecular Biology, 2008, 428, 125-140.	0.9	20
46	Identification of RUVBL1 and RUVBL2 as Novel Cellular Interactors of the Ebola Virus Nucleoprotein. Viruses, 2019, 11, 372.	3.3	19
47	Molecular pathology of prostate cancer. Cancer Biomarkers, 2011, 9, 441-459.	1.7	18
48	Onâ€ŧissue identification of insulin: In situ reduction coupled with mass spectrometry imaging. Proteomics - Clinical Applications, 2011, 5, 448-453.	1.6	18
49	Selective capture of prostatic basal cells and secretory epithelial cells for proteomic and genomic analysisâ ⁻ †. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 329-336.	1.6	17
50	Proteomic Expression Profiling and Identification of Serum Proteins Using Immobilized Trypsin Beads with MALDI-TOF/TOF. Journal of Proteome Research, 2009, 8, 4182-4192.	3.7	16
51	Pre-symptomatic diagnosis and treatment of filovirus diseases. Frontiers in Microbiology, 2015, 6, 108.	3.5	15
52	Heat fixation inactivates viral and bacterial pathogens and is compatible with downstream MALDI mass spectrometry tissue imaging. BMC Microbiology, 2015, 15, 101.	3.3	14
53	Serum protein expression profiling in pediatric Hodgkin lymphoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2008, 51, 216-221.	1.5	13
54	Development of a liquid chromatography high resolution mass spectrometry method for the quantitation of viral envelope glycoprotein in Ebola virus-like particle vaccine preparations. Clinical Proteomics, 2016, 13, 18.	2.1	13

#	Article	IF	CITATIONS
55	The distribution of dissolved DNA in an oligotrophic and a eutrophic river of Southwest Florida. Hydrobiologia, 1991, 218, 53-63.	2.0	11
56	Bioengineering of bacterial pathogens for noninvasive imaging and in vivo evaluation of therapeutics. Scientific Reports, 2018, 8, 12618.	3.3	11
57	Modeling mosquito-borne and sexual transmission of Zika virus in an enzootic host, the African green monkey. PLoS Neglected Tropical Diseases, 2020, 14, e0008107.	3.0	11
58	Signal Detection in High-Resolution Mass Spectrometry Data. Journal of Proteome Research, 2008, 7, 276-285.	3.7	10
59	Quality Control, Preparation, and Protein Stability Issues for Blood Serum and Plasma Used In Biomarker Discovery and Proteomic Profiling Assays. BioProcessing: Advances and Trends in Biological Product Development, 2004, 3, 45-50.	0.1	10
60	Correlation of nonspecific macromolecular labeling with environmental parameters during [3H]Thymidine incorporation in the waters of southwest florida. Microbial Ecology, 1990, 20, 21-35.	2.8	9
61	A study of DNA damage in buccal cells of consumers of well―and/or tapâ€water using the comet assay: Assessment of occupational exposure to genotoxicants. Environmental and Molecular Mutagenesis, 2017, 58, 619-627.	2.2	9
62	Characterization of the plasma proteome of nonhuman primates during Ebola virus disease or melioidosis: a host response comparison. Clinical Proteomics, 2019, 16, 7.	2.1	9
63	Characterization of Citrullination Sites in Neutrophils and Mast Cells Activated by Ionomycin via Integration of Mass Spectrometry and Machine Learning. Journal of Proteome Research, 2021, 20, 3150-3164.	3.7	9
64	Metabolomic Profiling of Human Urine Samples Using LC-TIMS-QTOF Mass Spectrometry. Journal of the American Society for Mass Spectrometry, 2021, 32, 2072-2080.	2.8	9
65	Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability. MAbs, 2022, 14, 2020081.	5.2	9
66	Tissue Sample Collection for Proteomics Analysis. Methods in Molecular Biology, 2008, 428, 43-53.	0.9	8
67	New Steroidal 4-Aminoquinolines Antagonize Botulinum Neurotoxin Serotype A in Mouse Embryonic Stem Cell Derived Motor Neurons in Postintoxication Model. Journal of Medicinal Chemistry, 2018, 61, 1595-1608.	6.4	7
68	Impact of Toll-Like Receptor-Specific Agonists on the Host Immune Response to the Yersinia pestis Plague rF1V Vaccine. Frontiers in Immunology, 2021, 12, 726416.	4.8	7
69	Identification of a superimmunoglobulin gene family member overexpressed in benign prostatic hyperplasia. , 2000, 42, 230-238.		6
70	Prostate cancer region prediction by fusing results from MALDI spectra–processing and texture analysis. Simulation, 2012, 88, 1247-1259.	1.8	6
71	Phosphatase Inhibitors Function as Novel, Broad Spectrum Botulinum Neurotoxin Antagonists in Mouse and Human Embryonic Stem Cell-Derived Motor Neuron-Based Assays. PLoS ONE, 2015, 10, e0129264.	2.5	6
72	SELDI-TOF-MS profiling of serum for early detection of colorectal cancer. Gastroenterology, 2003, 124, A650.	1.3	5

#	Article	IF	CITATIONS
73	A Look at Mass Spectral Measurement. Chance, 2003, 16, 24-28.	0.2	5
74	Paracrine IFN Response Limits ZIKV Infection in Human Sertoli Cells. Frontiers in Microbiology, 2021, 12, 667146.	3.5	5
75	Proteomic and fractal analysis of a phenotypic transition in the growth of human breast cells in culture. Journal of Statistical Mechanics: Theory and Experiment, 2007, 2007, P12006-P12006.	2.3	3
76	Improved signal processing and normalization for biomarker protein detection in broadâ€massâ€range TOF mass spectra from clinical samples. Proteomics - Clinical Applications, 2011, 5, 440-447.	1.6	3
77	Inactivation of West Nile virus in serum with heat, ionic detergent, and reducing agent for proteomic applications. Journal of Virological Methods, 2017, 248, 1-6.	2.1	3
78	Countering Zika Virus: The USAMRIID Response. Advances in Experimental Medicine and Biology, 2018, 1062, 303-318.	1.6	3
79	Approach to Cataract Surgery in an Ebola Virus Disease Survivor with Prior Ocular Viral Persistence. Emerging Infectious Diseases, 2020, 26, 1553-1556.	4.3	2
80	Early detection of Ebola virus proteins in peripheral blood mononuclear cells from infected mice. Clinical Proteomics, 2020, 17, 11.	2.1	2
81	Species-specific quantification of circulating ebolavirus burden using VP40-derived peptide variants. PLoS Pathogens, 2021, 17, e1010039.	4.7	2
82	P-552. Fertility and Sterility, 2006, 86, S339.	1.0	1
83	Adjacent slice prostate cancer prediction to inform MALDI imaging biomarker analysis. , 2010, , .		1
84	Combining Prostate Cancer Region Predictions from MALDI Spectra Processing and Texture Analysis. , 2010, , .		1
85	Proteomic Analysis of Non-human Primate Peripheral Blood Mononuclear Cells During Burkholderia mallei Infection Reveals a Role of Ezrin in Glanders Pathogenesis. Frontiers in Microbiology, 2021, 12, 625211.	3.5	1
86	Prostate cancer region prediction using MALDI mass spectra. , 2010, , .		0